Citadel Advisors
TPST icon

Citadel Advisors’s Tempest Therapeutics TPST Stock Holding History

Citadel Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,185
Closed -$21K – 15115
2025
Q1 		$21K Sell
2,185
-469
-18% -$5.32K ﹤0.01% 13107
2024
Q4 		$28.8K Buy
2,654
+539
+25% +$6.96K ﹤0.01% 12912
2024
Q3 		$38.5K Sell
2,115
-162
-7% -$3.32K ﹤0.01% 12178
2024
Q2 		$64.8K Buy
2,277
+1,239
+119% +$53.6K ﹤0.01% 11468
2024
Q1 		$52.8K Buy
1,038
+992
+2,157% +$50.1K ﹤0.01% 12129
2023
Q4 		$2.64K Buy
+46
New +$2.18K ﹤0.01% 13674
2021
Q2 		– Sell
-264
Closed -$62K – 14446
2021
Q1 		$62K Buy
+264
New +$107K ﹤0.01% 12796
2020
Q3 		– Sell
-98
Closed -$34K – 10741
2020
Q2 		$34K Buy
+98
New +$39.1K ﹤0.01% 9431
2017
Q2 		– Sell
-4
Closed -$21K – 8071
2017
Q1 		$21K Buy
+4
New +$18.6K ﹤0.01% 7235
2015
Q4 		– Sell
-5
Closed -$121K – 9203
2015
Q3 		$121K Buy
5
+4
+400% +$269K ﹤0.01% 6773
2015
Q2 		$69K Sell
1
-1
-50% -$91.6K ﹤0.01% 7430
2015
Q1 		$167K Buy
+2
New +$266K ﹤0.01% 6366

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors's TPST Position: Q2 2026 in Review

Citadel Advisors opened a new position in Tempest Therapeutics (TPST) in Q2 2026: 19,820 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #13385 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TPST as recently as Q2 2024.

Citadel Advisors first reported a position in TPST in Q1 2015 and has held it in 17 quarters since. The position peaked at $9.95M in Q1 2015. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Citadel Advisors held 19,820 shares of Tempest Therapeutics worth $22K as of Q2 2026.
  • Tempest Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Tempest Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13385 holding.
  • Citadel Advisors first reported a position in Tempest Therapeutics in Q1 2015 and has held it in 17 quarters since.
  • Citadel Advisors's Tempest Therapeutics position peaked at $9.95M in Q1 2015.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.